Treatment of patients with schizophrenia and substance abuse disorders

Current Pharmaceutical Design

Volumn 10, Issue 18, 2004, Pages 2249-2261

  Tsuang, John ^a   Fong, Timothy W ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Effective treatment of dual diagnosis patients; Substance abuse and schizophrenic population

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BUPRENORPHINE; CHLORDIAZEPOXIDE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DISULFIRAM; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LITHIUM; METHADONE; MUSCLE RELAXANT AGENT; NALTREXONE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERDAL CONSTANTA; RISPERIDONE; RISPERIDONE M TAB; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE;

DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; FAMILY THERAPY; GROUP THERAPY; HEALTH CARE UTILIZATION; HOMELESSNESS; HOSPITALIZATION; HUMAN; INTERVIEW; MENTAL DISEASE; MENTAL HEALTH; NONHUMAN; OUTCOMES RESEARCH; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUBSTANCE ABUSE; TARDIVE DYSKINESIA;

DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; PSYCHOTHERAPY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF-HELP GROUPS; SUBSTANCE-RELATED DISORDERS;

EID: 3042637917     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384114     Document Type: Review

References (191)

1. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518.
2. Schneier Fr, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: Patterns of drug choice. J Nerv Ment Dis 1987; 175(11): 641-652.
3. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: Implications for treatment. J Consult Clin Psychol 1992; 60: 845-856.
4. Soyka M, Albus M, Finelli A, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci 1993; 242: 362-372.
5. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia: A prospective community study. J Nerv Ment Dis 1989; 177: 408-414.
6. Owen RR, Fischer EP, Booth BM. Medication compliance and Substance abuse among patients with schizophrenia. Psychiatr Serv 1996; 47(8): 853-358.
7. Shaner A, Eckman TA, Roberts LJ, Wilkins JN, Tucker DE, Tsuang JW, et al. Disability income, cocaine use, and repeated hospitalization among schizophrenic cocaine abusers - a government-sponsored revolving door? N Engl J Med 1995; 333(12): 777-783.
8. Haywood TW, Kravitz HM, Grossman LS: Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995; 152: 856-861.
9. Swofford CD, Kasckow JW, Scheller GG. Substance use: A powerful predictor of relapse in schizophrenia. Schizophr Res 1996; 20: 145-51.
10. Dixon L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr Res 1999; 35: 93-100.
11. Green AI, Canuso CM, Brenner MJ, Wojtik JD. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 2003; 26(1): 115-139.
12. Dickey B, Normand SL, Weiss Rd, Drake Re, Azenie H. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv 2002; 53: 861-867.
13. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Bull 2002; 54: 253-264.
14. Ries R, Mullen M, Cox G. Symptom severity and utilization of treatment resources among dually diagnosed inpatients. Hospital and Community Psychiatry 1994; 45: 562-568.
15. Dickey B, Azeni H. Persons with dual diagnoses of substance abuse and major mental illness: Their excess costs of psychiatric care. Am J Public Health 1996; 86: 973-977.
16. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Washington, DC, American Psychiatric Association, 1994.
17. Carey KB. Clinically useful assessments: Substance use and comorbid psychiatric disorders. Behav Res Ther 2002; 40(11): 1345-1361.
18. Negrete JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med 1986; 16: 515-520.
19. Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996; 40: 1155-1163.
20. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-279.
21. Allebeck P, Adamsson C, Engstrom A. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand 1993; 88: 21-24.
22. Mueser KT, Fox L. A family intervention program for dual disorders. Community Ment Health J 2002; 38(3): 253-270.
23. Potvin S, Stip E, Roy J. Schizophrenia and addiction: An evaluation of the self-medication hypothesis. Encephale 2003; 29: 193-203.
24. Chambers RA, DW Self. Motivational responses to natural and drug rewards in rats withd neonatal ventral hippocampal lesions: An animal model of dual diagnosis schizophrenia. Neuropsychopharmacology 2002; 27(6): 889-905.
25. Shaner A, Roberts LJ, Eckman TA, Racenstein JM, Tucker DE, Tsuang JW, et al. Sources of diagnostic uncertainty for chronically psychotic cocaine abusers. Psychiatr Serv 1998; 49: 684-690.
26. Khantzian EJ. A self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142: 1259-1264.
27. Green AI, Saloman MS, Brenner MJ, Rawlins. Treatment of schizophrenia and comorbid substance se disorder. Curr Drug Targets CNS Neurol Disord 2002; 2: 129-139.
28. Mueser KT, Drake Re, Wallach MA. Dual diagnosis: A review of etiological theories. Addict Behav 1998; 23: 717-734.
29. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991; 148: 224-230.
30. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: implications for treatment. J Consult Clin Psychol 1992; 60: 845-856.
31. Lysaker P, Bell M, Beam-Goulet J, Milstein R. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Ment Dis 1994; 182: 109-112.
32. Lieberman JA, Kane MJ, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 1987; 91: 415-433.
33. Janowsky DS, Davis JM. Methypenidate, dextroamphetamine, and levanifetamine: effects of schizophrenic patients. Arch Gen Psychiatry 1976; 33: 304-308.
34. Richard ML, Liskow BI, Perry PJ. Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry 1985; 46: 79-83.
35. Dixon L, Haas G, Weiden P, Sweeney J, Frances A. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr Bull 1990; 16: 69-79.
36. Noordsy DL, Drake RE, Teague GB. Osher FC, Hurlbut SC, Beaudett MS. Subjective experiences related to alcohol use among schizophrenics. J Nerv Ment Dis 1991; 179 (7): 410-414.
37. Drake RE, Wallach MA, Alverson HS, Mueser KT. Psychosocial aspects of substance abuse by clients with severe mental illness. J Nerv Mental Dis 2002; 190: 100-106.
38. Drake RE, Mueser KT. Managing comorbid schizophrenia and substance abuse. Curr Psychiatric Rep 2001; 3: 418-422.
39. Lehman AF, Dixon L, Hoch JS, Deforge B, Kernan E, Frank R. Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness. Br J Psychiatry 1999; 174: 346-352.
40. Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis demographic characteristics, clinical features, and family history. Arch Gen Psychiatry 1982; 39: 141-147.
41. Tsuang M, Lyons M, Tsuang J, True W. Relationship of drug abuse to psychotic symptoms. Symposium presentation at the American Psychiatric Association. Annual Meeting 1997.
42. Krystal JH, D'Souza DC, Madonick S, Petrakis, IL. Toward a rational pliarmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 1999; 35: S35-S49.
43. Chambers AC, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001; 50(2): 71-83.
44. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trend Pharmacol Sci 1992; 13: 177-184.
45. Goldstein M, Deutch AY. Dopaminergic mechanisms in the pathogenesis ofschizophrenia. FASEB J 1992; 6: 2413-2421.
46. Keverne EB. GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Brain Res Bulletin 1999; 48: 467-473.
47. Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull 2000; 26: 105-118.
48. Bellack AS, Gearon JS. Substance abuse treatment for people with schizophrenia. Addict Behav 1998; 23(6): 749-766.
49. Bellack AS, Diclemente C. Treating substance abuse among patients with schizophrenia. Psychiatr Serv 1999; 50: 75-80.
50. Glazer WM, Morgenstern H. Predictors of occurrence, severity, and course of TD in an outpatient population. J Clin Psychopharmacol 1988; 8: 10S-16S.
51. Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. Am J Drug Alcohol Abuse 1990; 16(1-2): 57-66.
52. Zaretsky A, Rector NA, Seeman MV, Fornazzari X. Current cannabis use and tardive dyskinesia. Schizophr Res 1993; 11(1): 3-8.
53. Bailey L, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: A retrospective analysis of 1, 027 patients. Psychopharmacol Bull 1997; 22(1): 177-181.
54. Dixon L, Weiden PJ, Haas G, Sweeney J, Frances AJ. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992; 33(2): 121-122.
55. Siegfried SI, Fleishchacker W, Lieberman JA. Pharmacological treatment of schizophrenia. In: Lieberman JA, Murray RM, editors. Comprehensive Care of Schizophrenia. London: Martin Dunitz; 2001. p. 59-94.
56. Harvey PD, Keefe RE. Cognition and the new antipsychotics. J Adv Schizophr Brain Res 1998; 1: 2-8.
57. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 2003; 60: 81-85.
58. Ziedonis D, D'Avanzo K. Schizophrenia and substance abuse. In: Kranzler HR, Rounsaville BJ, eds. Dual Diagnosis and Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders. New York: Marcel Dekker, Inc. 1998, 427-459.
59. Buckley PF. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat 1998; 15(2): 113-116.
60. Soyka M. Dual diagnosis in patients with schizophrenia: issues in pharmacological treatment. CNS Drugs 1996; 5(6): 414-425.
61. Kosten TA, Nestler EJ. Clozapine attenuates cocaine conditioned place preference. Life Sci 1994; 55: PL9-14.
62. Roberts DCS, Vickers G. Atypical neuroleptics increase self-administration of cocaine: An evaluation of a behavioral screen for antipsychotic activity. Psychopharmacology 1984; 82: 135-139.
63. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine (letter). Am J Psychiatry 1995; 152: 959.
64. McEvoy J, Freudenreich O, McGlee M, Vander Zwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Society of Biological Psychiatry 1995; 37: 550-552.
65. Albanese MJ, Khantzian EJ, Murphy SI. Decreased substance use in chronically psychotic patients treated with clozapine (letter). Am J Psychiatry 1994; 151: 780-781. Yovell 1994
66. Tsuang J, Eckman T, Shaner A, Marder S. Clozapine for substance abusing schizophrenic patients. Am J Psychiatry 1999; 156(7): 1119-1120.
67. Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: A case report and a hypothesis. J Nerv Ment Dis 1994; 182(10): 591-592.
68. Buckley PF. Substance abuse in schizophrenia: A review. J Clin Psychiatry 1998; 59 Suppl 3: 26-30.
69. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bull 2000; 26(2): 441-449.
70. Buckley PF, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant Schizophrenia: Characteristics and implications for clozapine therapy. Am J Psych 1994; 151: 385-389.
71. Smelson DA, Roy A, Roy M. Risperidone and neuropsychological test performance in cocaine-withdrawn patients. Can J Psychiatry 1997; 42: 431.
72. Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002; 47: 671-675.
73. Tsuang JW, Eckman T, et al. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol 2002; 22(6): 629-630.
74. Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res 2001; 102: 227-233
75. Fong TW, Newton TF, Kalechstein AD, Hooper KB, Ling W. Risperidone blunts cocaine-induced craving for cocaine (abstract). Drug Alcohol Depend 2001; 63(1): S48.
76. Sakhi S, Newton TF, Kalechstein AD, Uslaner J, Tervo K, Ling W. Risperidone reduces euphoric effects of cocaine (abstract). Drug Alcohol Depend 2001; 63(1): S137.
77. Roy A, Roy M, Smelson D. Risperidone, ERG, and cocaine craving (letter). Am J Addict 1998; 7(1): 90.
78. Albanese M. Risperidone in substance abusers with bipolar disorder. Abstract presented at: 39t Annual Meeting of the American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico; December 10-14, 2000.
79. Albanese MJ. Safety and efficacy of risperidone in substance abusers with psychosis. Am J Addict 2001; 10: 190-191.
80. Huang CC. Risperdal reduces alcohol use in dual disabled schizophrenic patients. Eur Neuropsychopharmacol 1996; 6(3): 43.
81. Grabowski J, Rhoades H, Silverman P, Schmitz JM, Stotts A, Creson D, et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol 2000; 20: 305-310.
82. Berk M, Brook S, Nor F. Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int J Psych Clin Pract 2000; 4: 139-142.
83. Wachtel SR, Ortengren A, de Wit H. The effects of acute haloperidol on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend 2002, 68(1): 23-33.
84. Treatment of special Populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. J Clin Psychiatry 1998; 59(suppl 12): 46-52.
85. Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatry 1997; 58 suppl 10: 18-21.
86. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998; 33: 95-101.
87. Littrell KH, Peabody CD, Littrell SH. Olanzapine: a new atypical antipsychotic. J Psychosoc Nurs Ment Health Serv. 1996; 34(8): 41-46.
88. Longo LP. Olanzapine for cocaine craving and relapse prevention in 2 patients. J Clin Psychiatry 2002; 63(7): 595-596.
89. Tsuang J, Eckman T, et al. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry 2002; 63(12): 1180-1181.
90. Cruz HA, Haider S. Effectiveness of quetiapine in patients with dual diagnosis (poster). Presented at the: APA Institute on Psychiatr Serv, October 10-14, 2002; Orlando, FL.
91. Brown ES, Nejtek VA, Perantie DC, Bobadilla L. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 2002; 4: 406-411.
92. Brown ES, Nejtek BA, Perantie DC. Neuroleptics and quetiapine in psychiatric illnesses with comorbid stimulant abuse (poster). Presented at: the Society of Biological Psychiatry Annual Meeting, May 16-18, 2002; Philadelphia, PA.
93. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of Divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Nueropsychopharmacology 2003; 28(1): 182-192.
94. Casey DE, Atypical antipsychotics: enhancing healthy outcomes. Arch Psychiatr Nurs 2002; 16(3 supp] 1): S12-S19.
95. Casey DE. Clinical trial design issues in schizophrenic research. J Clin Psychiatry 2001; 62 suppl 9: 17-20, discussion 21-22.
96. Ziedonis DM, Kosten TR. Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J Psychoactive Drugs 1991; 23: 417-425.
97. Kosten TR. Pharmacotherapeutic interventions for cocaine abuse matching patients to treatment. J Nerv Ment Dis 1989, 177: 379-389.
98. Ziedonis D, Richardson T, Lee E, Petrakis I, Kosten T. Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 1992; 28(3): 309-314.
99. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992; 53: 426-433.
100. Davis M, Metalon L, Watanabe MD, Blake J. Depot antipsychotic drugs: Place in therapy. Drugs 1994; 47(5): 741-773.
101. Soyka M, Sand P. Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism. Pharmaco-psychiatry 1995; 28: 64-65.
102. Schilkrut R, Cabrera J, Morales E, et al. Neuroleptics in the treatment of drug dependence in schizophrenics: A study with flupenthixol decanoate (abstract no. 33.01.50). Psychopharmacology 1988; 96 Suppl.: 342.
103. Kane JM, Erdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003, 160(6): 1125-32.
104. Bickel WKI, Stitzer ML, Begelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine comparison with methadone in the detoxification of heroin addicts. Clin Pharm Ther 1988; 43: 72-78.
105. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35: 501-516.
106. Welsh C, Liberto J. The use of medication for relapse prevention in substance dependence disorders. Journal of Psychiatric Practice 2001; 7(1): 15-31.
107. Kinsbury SJ, Salzman C. Disulfiram in the treatment of alcoholic patients with schizophrenia. Hospital Community Psychiatry 1990; 41: 133-134.
108. O'Malley S, Adamse M, Heaton RK, Gawin FH. Neuropsychological impairment in chronic cocaine abusers. Am J Drug Alcohol Abuse 1992; 18: 131-144.
109. Volpicelli JT, et al. Naltrexone in treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876-880.
110. Dougherty RJ. Natrexone in the treatment of alcohol dependent dual-diagnosed patiens. (abstract). J Addict Dis 1997; 16: 107.
111. Maxwell S, Shinderman MS. Naltrexone in the treatment of dually-diagnosed patients (abstract). J Addic Dis 1997; 16: 107.
112. Rao S, Ziedonis D, Kosten T. The pharmacotherapy of cocaine dependence. Psychiatric Annals 1995; 25: 363-368.
113. Wilkins JN. Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull 1997; 23: 215-228.
114. Siris S. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 1990; 16: 111-122.
115. Seibyl J. Personal communication on mazindol study, 1993.
116. Johnson R, et al. Mazindol augmentation of neuroleptics in cocaine abusers. 1993 New Research Program and Abstracts. Washington, DC: American Psychiatric Association, 1992: 92.
117. Ritz MC, et al. Cocaine receptors on dopamine transporters are related to self-administration of cocaine, Science 1987; 44: 660-669.
118. Schein JR. Cigarette smoking and clinically significant drug interactions. Annals of Pharmacotherapy 1995; 29: 1139-1148.
119. Shimoda K, Someya T, Morita S, Hirokane G, Noguchi T, Yojono S, et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Ther Drug Monit 1999; 21: 293-296
120. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot-smoking cessation prograrn and review of neurobiological and clinical issues. Schizophr Bull 1997; 23: 247-254.
121. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57(suppl): 12-25.
122. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999; 60 suppl 10: 20-30.
123. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 6: 383-390.
124. De Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995; 152: 453-455.
125. Salokangas RK, Saarijarvi S, Taiminen T, Lehto H, Nieme H, Ahola V, et al. Effect of smoking on neuroleptics in schizophrenia. Schnizophr Res 1997; 23: 55-60.
126. American Psychiatric Association. APA Practice Guideline for the Treatment of Patients with Nicotine Dependence. Am J Psychiatry 1996.
127. Ziedonis DM, George TP. Schizophrenia and nicotine use Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997, 23(2): 247-254.
128. Addington J. Group treatment for smoking cessation among persons with schizophrenia. Psych Serv 1998; 49: 925-928.
129. Dalack GW, Meador-Woodruff JH. Smoking, smoking withdrawal and schizophrenia: Case reports and a review of the literature. Schiz Res 1996; 22: 133-141.
130. George TP, Sernyak MJ, Ziedonis DM, Woods SW. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56: 344-346.
131. Oyewumi LK. Smoking cessation and clozapine side effects. Can J Psychiatry 1998; 43: 748.
132. Bustillo JR, Lauriello, Keith SJ. Schizophrenia: Improving outcome. Harv Rev Psychiatry 1999; 5: 229-240.
133. Drake RE, Essock SE, Shaner A. Implementing dual diagnosis services for client with severe mental illness. Psychiatr Serv 2001; 52: 469-476.
134. Judd PH, Thomas N, Schwartz T, Outcalt A, Hough R. A dual diagnosis demonstration project: Treatment outcomes and cost analysis. J Psychoactive Drugs 2003; 35: 181-192.
135. Klinkenberg WD, Calsyn RJ. Predictors of receipt of aftercare and recidivism among persons with severe mental illness: A review. Psychiatric Services 1996; 47: 487-497.
136. Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull 1998; 24: 589-608.
137. Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull 1998; 24(4): 589-608.
138. Minkoff K. Developing standards of care for individuals with cooccurring psychiatric and substance use disorders. Psychiatr Serv 2001; 52: 597-599.
139. Bellack AS, Diclemente C. Treating substance abuse among patients with schizophrenia. Psychiatr Serv 1999; 50: 75-80.
140. Tsuang J, Ho A, Eckman T, Shaner A. Dual diagnosis treatment for patients with schizophrenia who abuse psychostimulants: rehab rounds. Invited article. Psychiatr Serv 1997; 48(7): 887-889.
141. Ho AP, Tsuang JW, Liberman RP, Wang R, Wilkins JN, Eckman TA, et al. Achieving effective treatment of patients with chronic psychotic illness and comorbid substance dependence. Am J Psychiatry 1999, 156: 1765-1770.
142. Torrey WC, Drake RE, Cohen M, Fox LB, Lynde D, Gorman P, et al. The challenge of implementing and sustaining integrated dual disorders treatment programs, Community Ment Health J 2002, 38: 507-521.
143. Drake RE, Yovertich NA, Bebout RR, Harris M, McHugo GJ. Integrated treatment for dually diagnosed homeless adults. J Nerv Ment Dis 1997; 185: 298-230.
144. Havassy BE, Shopshire MS, Quigley LA. Effects of substance dependence on outcomes of patients in a randomized trial of two case management models. Psychiatr Serv 2000; 51: 639-644.
145. Bradizaa CM, Stasiewicz PR. Integrating substance abuse treatment for the seriously mentally ill into psychiatric treatment. J Subst Abuse Treat 1997; 14: 103-111.
146. Cuffel B, Shumway M, Chouljian T. A longitudinal study of substance use and community violence in the schizophrenia. J Nerv Ment Dis 1994; 182: 704-708.
147. Moggi F, Crosby P, Moos RH, Finney JW. Dual diagnosis patients in substance abuse treatment: Relationship of general coping and substance-specific coping to 1-year outcomes. Addiction 1999; 94: 1805-1916.
148. Mercer-McFadden C, Drake RE, Brown NB, Fox RS. The community support program demonstration of services for young adults with severe mental illness and substance use disorders. Psychiatric Rehab Journal 1997; 20: 13-24.
149. Jerrell JM, Ridgely MS. Impact of robustness of program implementation on outcomes of clients in dual diagnosis programs. Psychiatr Serv 1999; 50: 109-112.
150. Hellerstein DJ, Rosenthal RN, Miner CR. A prospective study of integrated outpatient treatment for substance-abusing schizophrenic patient. Am J Addict 1995; 4: 33-42.
151. Clark RE, Teague GB, Ricketts SK, Bush PW, Xie H, McGuire TG, et al. Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders. Health Serv Res 1998; 33: 1285-1308.
152. Lauriello J, Lenroot R, Bustillo JR. Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatr Clin North Am 2003; 26(1): 191-211.
153. Graeber DA, Moyers TB, Griffith G, Guajardo E, Tonigan S. A pilot study comparing motivational and and educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J 2003; 39: 189-202.
154. Miller WR, Yahne CE, Tonigan JS. Motivational interviewing in drug abuse services: a randomized trial. J Consult Clin Psychol 2003; 71(4): 754-763.
155. Swanson AJ, Pantalon MV, Cohen KR. Motivational interviewing and treatment adherence among psychiatrically and dually diagnosed patients. J Nerv Ment Dis 1999; 187(10): 630-635.
156. Martino SK, Carroll, et al. Dual diagnosis motivational interviewing for substance abusing patients with psychotic disorders. J Subst Abuse Treat 2002; 23(4): 297-308.
157. Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001; 158: 1706-1713.
158. Powell T, Kurtz L, Garvin C, Hill E. A model of AA. Utilization by persons with a dual diagnosis. Contemporary Drug Problems 1996, 23:139-157.
159. Kurtz LF, Garvin CD, Hill Em, Pollio D, McPherson S, Powell TJ. Involvement in alcoholics anonymous by persons with dual disorders. Alcoholism Treatment Quarterly 1995; 12: 1-18.
160. Jordan LC, Davidson WS, Herman SE, Bootsmiller BJ. Involvement in 12-step programs among persons with dual diagnoses. Psychiatr Serv 2002; 53: 894-896.
161. Magura S, Laudet A, Mahmood D, Rosenblum A, Knight E. Medication adherence and participation in self-help groups designed for dually diagnosed persons. Psychiatr Serv 2002; 53: 310-316.
162. Magura S, Lauder A, Mahmood D, Rosenblum A, Knight E. Role of self-help processes in achieving abstinence among dually diagnosed persons. Addict Behav 2003; 28: 399-413.
163. Laudet AB, Magura S, Cleland CM, Vogel HS, Knight EL. Predictors of retention in dual-focus self-help groups. Community Ment Health J 2003; 39: 281-297.
164. Beck AT, Rector NA. Cognitive therapy of schizophrenia: a new therapy for the new millennium. Am J Psychother 2000; 54(3): 291-300.
165. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression. New York: Guilford Press, 1979.
166. Beck AT, Cognitive therapy and the emotional disorders. New York: International Universities Press, 1976.
167. Fairburn CG. Cognitive-behavioral treatment for bulimia. In D.M. Garner & P.E. Garfinkel (Eds.), Handbook of Psychotherapy for anorexia nervosa and bulimia. New York: Guilford Press, 1985.
168. Linehan MM. Cognitive behavioral treatment of borderline personality disorder: the dialectics of effective treatment. New York: Guilford Press, 1993.
169. Kohlenberg RJ, Tsai M. Functional analytic psychotherapy: creating intense curative therapeutic relationships. New York: Plenum, 1991.
170. Tarrier N, Haddock G, Barrowclough C, Wykes T. Are all psychological treatments for psychosis equal? The need for CBT in the treatment of psychosis and not for psychodynamic psychotherapy. Psychol Psychother. 2002; 75(Pt 4): 365-374.
171. Tarrier N, Kinney C, McCarthy E, Humphreys L, Wittkowski A, Morris J. Two-year follow-up of cognitive-behavioral therapy and supportive counseling in the treatment of persistent symptoms in chronic schizophrenia. J Consult Clin Psychol 2000; 68(5): 917-922.
172. Tarrier N, Sommerfield C, Pilgrim H, Humphreys L. Cognitive therapy or imaginal exposure in the treatment of post-traumatic stress disorder. Br J Psychiatry 1999; 175: 571-575.
173. Carey KB. Substance use reduction in the context of Outpatient psychiatric treatment: A collaborative, motivational, harm reduction approach. Community Ment Health J 1996; 32: 291-306.
174. Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, et al. Cognitive-behavioral treatment for persistent symptoms in schizophrenia. Arch Gen Psychiatry 2000; 57: 165-173.
175. Nigram R, Schottenfield R, Kosten TR. Treatment of dual diagnosis patients: A relapse prevention group approach. J Subst Abuse Treat 1992; 9: 304-309
176. Roder V, Brenner HD, Muller D, Lachler M, Zorn P, Reisch J, et al. Development of specific social skills training programmes for schizophrenia patients: results of a multicentre study. Acta Psychiatr Scand 2002; 105: 363-371.
177. Roberts LJ, Shaner A, Eckmas T. Overcoming addiction: Skills training for people with schizophrenia. Norton Professional Books, NY 1999.
178. Shaner A, Eckman T, Roberts L, Fuller T. Feasibility of a skills training approach to reduce Substance dependence among individuals with schizophrenia. Psychiatr Serv 2003, 54: 1287-1289.
179. Higgins ST, Delaney DD, Budney AJ, Bickel WK, Hughes JR, Foerg F, et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry 1991; 148(9): 1218-1224.
180. Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994; 51(7): 568-576.
181. Higgins ST, Petry NM. Contingency management. Incentives for sobriety. Alcohol Res Health 1999; 23(2): 122-127.
182. Petry N. A comprehensive guide to the application of contingency management procedures in clinical settings, Drug Alcohol Depend 2000; 58: 9-25.
183. Shaner A, Roberts LJ, Eckman TA, Tucker DE, Tsuang JE, Wilkins JN, et al. Monetary reinforcement of abstinence from cocaine among mentally ill patients with cocaine dependence. Psychiatr Serv 1997; 48: 807-810.
184. Sigmon SC, Steingard S, Badger GJ, Anthony SJ, Higgins ST. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: A feasibility study. Exp Clin Psychopharmacology 2000; 8: 509-517.
185. Mueser KT, Fox L. A family intervention program for dual disorders. Community Ment Health J 2002; 38)3): 253-270.AA
186. Rosenberg H, Phillips KT. Acceptability and availability of harm-reduction interventions for drug abuse in American substance abuse treatment agencies. Psychol Addict Behav. 2003, 17(3): 203.210.
187. Marlatt GA, Witkiewitz K. Harm reduction approaches to alcohol use Health promotion, prevention and treatment. Addict Behav 2002; 27: 867-886.
188. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug Dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000; 284: 1689-1695.
189. Covelli V, Pellegrino NM, Jirillo E. A point of view: The need to identify an antigen in psyconeuroimmunological disorders. Curr Pharm Design 2003; 9(24): 1951-5.
190. Ito C. Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia. Curr Pharm Design 2002; 8(2): 147-53.
191. Luedtkea RR, Mach RH. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Curr Pharm Design 2003; 9(8): 643-71.